Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
SAN FRANCISCO, CA and TOKYO – December 12, 2014 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (Tokyo: 4503), announced today the presentation of Stage 1 and preliminary Stage 2...
TOKYO, JAPAN – December 10, 2014 – Astellas Pharma Inc. (Tokyo: 4503), announced today that Stage 1 and preliminary Stage 2 data from a Phase 2 study evaluating the use of enzalutamide as a...
Tokyo, Dec. 9, 2014 – Astellas Pharma Inc. (TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) announced that it has been selected for the third year to be included in the...
Read more about Astellas Named to FTSE4Good Sustainability Index for the Third Year
TOKYO, Japan - December 2, 2014 - Astellas Pharma Inc. (TSE: 4503) (“Astellas”) announced that its license agreement with Janssen Biotech, Inc. (“Janssen”) to develop and commercialize...
Tokyo, December 2, 2014 –Astellas Pharma Inc. (TSE: 4503, “Astellas”) today announced that the European Commission (EC) has granted a variation to amend the Marketing Authorisation for...
The additional sub-group analyses of C-OPERA in findings regarding the inhibition of joint structural destruction were reported at the American College of Rheumatology/Association of Rheumatology...
Tokyo, Japan - Nov. 4, 2014 – Astellas Pharma Inc. (Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) announced for the fifth consecutive year, Astellas Group’s global volunteer...
Follow us
